Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 May 9;292(26):11009–11020. doi: 10.1074/jbc.M116.768176

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

PMC Copyright notice

Figure 5. — Pharmacological inhibition of Toxoplasma-induced LD accumulation. A, fluorescent micrographs of HFFs that were infected with RH(TdTomato) Toxoplasma and treated with the indicated drugs for 24 h. To visualize LD accumulation, cells were pulsed with 360 μm OA for the last 6 h of infection. Scale bars = 20 μm. B, cellular TAG was quantified for HFFs infected for 24 h and treated with the indicated drugs (n = 3). All infected samples were normalized to an uninfected (Uninf) control. One-way ANOVA: *, p < 0.05;**, p < 0.001; ***, p < 0.0001. C and D, qPCR comparing host transcript levels of DGAT2 (C) and FABP5 (D) after infection and drug treatment. All samples are normalized to infected (Inf)/DMSO control. Significance was tested by one-way ANOVA. B–D, drugs that showed no significant effect on LD accumulation are shaded light gray.